Fig. 1 · Structure

Documents & Downloads

Daclatasvir (BMS-790052)

Cat. No. A10159 CAS 1009119-64-5

HCV NS5A inhibitor

BMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.

In Stock

Publications for Daclatasvir

3 publications citing this product

  1. TS Wahyuni, .et al. , Southeast Asian J Trop Med public health, 2020, 51(1)
  2. Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
  3. Sato K, .et al. , Hepatol Res, 2018, Feb;48(3):E347-E353 PMID: 28834004

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BMS-790052 (daclatasvir) binds directly to isolated HCV NS5A domain 1. In microscale thermophoresis, the reported KD was 8 ± 3 nM for the genotype 1b fragment spanning residues 33–202 and 210 ± 46 nM for residues 26–202, showing that the measured affinity depends on the protein construct. [1]

In an isolated NS5A fragment assay, 0.25 μM BMS-790052 reduced affinity for a short uridine RNA: the reported RNA KD changed from 50 ± 15 nM to 94 ± 11 μM. This supports a biochemical effect on RNA binding; the fragment assay does not establish the complete mechanism in cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
CCRF-CEM CC50 9.6 μM Cytotoxicity against human CEM cells after 3 days [PMID: 22507961]
Huh-7 CC50 > 10 μM Cytotoxicity against human HuH7 cells infected with HCV1b by Alamar blue fluorescence assay [PMID: 24521299]
Huh-7 EC50 0.003 nM Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by cell-based replicon assay [PMID: 25148100]
Huh-7 EC50 0.009 nM Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay [PMID: 24521299]
Huh-7 EC50 0.009 nM Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay [PMID: 24320933]
Huh-7 EC50 0.01 nM Antiviral activity against HCV 1b infected in human HuH7 cells by in vitro replicon assay [PMID: 23466233]
Huh-7 EC50 0.023 nM Inhibition of NS5A in HCV genotype-1b infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453810]
Huh-7 EC50 0.05 nM Antiviral activity against HCV1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay [PMID: 24521299]
Huh-7 EC50 0.05 nM Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay [PMID: 24320933]
Huh-7 EC50 0.051 nM Antiviral activity against HCV genotype 5a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 0.073 nM Antiviral activity against HCV genotype 1b infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 0.14 nM Antiviral activity against HCV genotype 1a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 0.14 nM Inhibition of NS5A in HCV genotype-1a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453810]
Huh-7 EC50 0.41 nM Antiviral activity against HCV genotype 4a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 0.45 nM Antiviral activity against HCV genotype 6a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 0.67 nM Antiviral activity against HCV genotype 3a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 0.67 nM Antiviral activity against HCV genotype 2a infected in human HuH7 cells by luciferase reporter gene assay [PMID: 25453811]
Huh-7 EC50 6.6 pM Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication by RT-PCR analysis [PMID: 22507961]
PBMC CC50 19 μM Cytotoxicity against human PBMC after 3 days [PMID: 22507961]
Vero CC50 21 μM Cytotoxicity against african green monkey Vero cells after 3 days [PMID: 22507961]

20 records · Scroll to view more

Daclatasvir (BMS-790052) Research Summary

This section summarizes 3 in vitro studies of Daclatasvir (BMS-790052) from 2 published references.

Daclatasvir (BMS-790052) In Vitro Studies

In the reported cellular replicon panel, BMS-790052 had EC50 values of 50 ± 13 pM for genotype 1a H77 and 9 ± 4 pM for genotype 1b Con1. The Huh-7 cytotoxicity endpoint was 17 ± 1 μM. These are model-specific assay endpoints; the table does not define the meaning of ± or identify a replicate count for these rows. [2]

Direct NS5A binding depends on the protein fragment

Biochemical assay · Isolated HCV genotype 1b (Con1) NS5A domain 1 fragments, residues 33–202 and 26–202. [1]

Microscale thermophoresis detected direct binding to both fragments, with weaker affinity for the longer fragment. These are biochemical dissociation constants, not cellular EC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to NS5A residues 33–202KD 8 ± 3 nM[1]
Binding to NS5A residues 26–202KD 210 ± 46 nM[1]

Literature-Reported Treatment Conditions

Method
Ligand-binding concentration series measured by MST using labelled isolated protein.
Vehicle
5% DMSO in the final MST assay buffer.
Reported limits
No treatment dose is implied by KD. Counterion is unspecified. Independent protein preparations are not enumerated; do not equate triplicate curves with biological replicates.
Methods and source locations

Compound reported in the paper: BMS-790052 (daclatasvir); Compound label in the paper: BMS-790052

Results apply to the authors’ BMS-790052 material and specified models; they do not validate an Adooq lot or define salt-specific performance.

Results: NS5A inhibitors bind to domain 1 of NS5A and compete with RNA binding; Figures 2e and 3e; Methods: Materials and MST.

Binding to NS5A residues 33–202: Microscale thermophoresis (MST); reported fitted affinity. Curves determined in triplicate, displayed as mean ± SD. — Figure 2e and caption; Results, NS5A inhibitors bind to domain 1; Methods, MST.

Binding to NS5A residues 26–202: MST; reported fitted affinity. Curves determined in triplicate, displayed as mean ± SD. — Figure 3e and caption; Results, NS5A inhibitors bind to domain 1; Methods, MST.

Reduced RNA affinity in an isolated-protein assay

Biochemical assay · HCV genotype 1b (Con1) NS5A residues 33–202; short single-stranded five-uridine RNA (5rU). [1]

Preincubation with BMS-790052 reduced the measured affinity of the isolated fragment for 5rU. The assay supports a biochemical effect on RNA binding, while the exact binding pose remains a model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
5rU binding without inhibitorKD 50 ± 15 nM[1]
5rU binding following preincubation with BMS-790052KD 94 ± 11 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.25 μM BMS-790052 in the inhibitor-preincubation condition.
Method
Comparison of RNA-binding affinity with and without inhibitor preincubation.
Vehicle
5% DMSO in the final MST assay buffer.
Reported limits
Preincubation duration is not specified in the read relevant description. A short RNA and truncated protein cannot establish the full cellular mechanism.
Methods and source locations

Compound reported in the paper: BMS-790052 (daclatasvir); Compound label in the paper: BMS-790052

Results apply to the authors’ BMS-790052 material and specified models; they do not validate an Adooq lot or define salt-specific performance.

Figure 2b,i and caption; Results: NS5A inhibitors bind to domain 1 of NS5A and compete with RNA binding; Methods: MST.

5rU binding without inhibitor: MST; triplicate binding curves displayed as mean ± SD. — Figure 2b; Results, In vitro NS5A binding assay; Figure 2 caption.

5rU binding following preincubation with BMS-790052: MST; triplicate binding curves displayed as mean ± SD. — Figure 2i; Results, NS5A inhibitors bind to domain 1; Figure 2 caption.

Cellular potency with a parallel cytotoxicity endpoint

Cell-based study · HCV genotype 1a H77 and genotype 1b Con1 replicon systems; Huh-7 hepatoma-cell cytotoxicity. [2]

BMS-790052 showed picomolar half-maximal inhibition in the two reported replicon models, with a micromolar Huh-7 cytotoxicity endpoint. These assay results are not clinical doses or evidence that every viral genotype responds identically.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Genotype 1a H77 replicon inhibitionEC50 50 ± 13 pM[2]
Genotype 1b Con1 replicon inhibitionEC50 9 ± 4 pM[2]
Half-maximal Huh-7 cytotoxicity endpointCytotoxicity 17 ± 1 μM[2]

Literature-Reported Treatment Conditions

Method
Cell-based replication-inhibition and cytotoxicity endpoints. The methods describe FRET and luciferase formats and a DMSO-only viability control.
Vehicle
DMSO controls are described for the luciferase/cytotoxicity format; Table 1 does not assign a format to each row.
Reported limits
Table 1 does not assign assay format, treatment duration, replicate count or ± definition to each row. The luciferase format specifies a 72 h exposure, but that duration is not assigned here to all table rows. EC50 values are endpoints, not treatment concentrations.
Methods and source locations

Compound reported in the paper: BMS-790052 (daclatasvir); Compound label in the paper: BMS-790052

Results apply to the authors’ BMS-790052 material and specified models; they do not validate an Adooq lot or define salt-specific performance.

Table 1 (genotype 1a H77, genotype 1b Con1 and Huh-7 cytotoxicity rows); opening compound-profile paragraph; Figure 1; Online Methods: Replicon assays (endpoint/control portions).

Genotype 1a H77 replicon inhibition: Cell-based replicon inhibition; original Table 1. The table does not state the replicate count or define ±. — Table 1, HCV replicon genotype 1a, H77 row.

Genotype 1b Con1 replicon inhibition: Cell-based replicon inhibition; original Table 1. The table does not state the replicate count or define ±. — Table 1, HCV replicon genotype 1b, Con1 row.

Half-maximal Huh-7 cytotoxicity endpoint: Table 1 cytotoxicity row; described luciferase-format assay assesses cell viability with CellTiter-Blue and DMSO-only controls. Table 1 groups this row under an EC50 header; the main profile paragraph discusses the CC50/EC50 index. — Table 1, Cytotoxicity Huh-7 cells row; Online Methods, Replicon assays; opening profile paragraph.

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1009119-64-5
Alternate CAS 1214735-16-6
Applications HCV NS5A inhibitor
Formula C40H50N8O6
Molecular Weight 738.9
Synonyms BMS-790052
SMILES
CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 129 mg/mL (174.59 mM)
Water Insoluble
Ethanol 129 mg/mL (174.59 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Daclatasvir (BMS-790052) Research References

  1. [1] Ascher DB, Wielens J, Nero TL, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA Scientific reports (2014). PMID: 24755925 DOI: 10.1038/srep04765 Source material
  2. [2] Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature (2010). PMID: 20410884 DOI: 10.1038/nature08960 Source material

Publications

3 publications citing this product

  1. TS Wahyuni, .et al. , Southeast Asian J Trop Med public health, 2020, 51(1)
  2. Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
  3. Sato K, .et al. , Hepatol Res, 2018, Feb;48(3):E347-E353 PMID: 28834004

Added to your cart

View Cart Checkout
Loading...